47.61
+0.01(+0.02%)
Currency In USD
| Previous Close | 47.6 |
| Open | 47.62 |
| Day High | 47.7 |
| Day Low | 47.59 |
| 52-Week High | 47.7 |
| 52-Week Low | 11.56 |
| Volume | 988,513 |
| Average Volume | 655,598 |
| Market Cap | 1.22B |
| PE | -13.84 |
| EPS | -3.44 |
| Moving Average 50 Days | 23.4 |
| Moving Average 200 Days | 18.83 |
| Change | 0.01 |
If you invested $1000 in Tourmaline Bio, Inc. (TRML) since IPO date, it would be worth $659.6 as of September 15, 2025 at a share price of $47.61. Whereas If you bought $1000 worth of Tourmaline Bio, Inc. (TRML) shares 3 years ago, it would be worth $2,828.88 as of September 15, 2025 at a share price of $47.61.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG
GlobeNewswire Inc.
Sep 09, 2025 5:03 AM GMT
– Novartis to acquire Tourmaline Bio for $48.00 per share in cash for a total equity value of approximately $1.4 billion – – Transaction reflects the potential of Tourmaline’s pacibekitug, a long-acting, fully-human, anti-IL-6 monoclonal antibody wit
Tourmaline Bio Presents Data from the Ongoing Phase 2 TRANQUILITY Trial at the 2025 European Society of Cardiology Congress
GlobeNewswire Inc.
Aug 31, 2025 2:23 PM GMT
– Poster presentation highlights the consistency of reductions in high-sensitivity C-reactive protein with pacibekitug across clinically-meaningful subgroups – – Pacibekitug demonstrated concordant, statistically significant reductions in secondary p
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025
GlobeNewswire Inc.
May 19, 2025 8:05 PM GMT
NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and